Although amino acid mixtures enriched in branched-chain amino acids (BCAA) and deficient in aromatic amino acids (AAA) are often used together with insulin and glucose in clinical nutrition, their physiological effects on muscle protein anabolism are not known. To this aim, we studied forearm leucine kinetics in post-absorptive volunteers, before and after the systemic infusion of BCAA-enriched, AAA-deficient amino acids along with insulin and the euglycaemic clamp. The results were compared with the effects of insulin infusion alone. A compartmental leucine forearm model was employed at steady state. Hyperaminoacidaemia with hyperinsulinaemia (to $ 80-100 µ-units/ml) increased the leucine plasma concentration (j70 % ; P 0.001), inflow into the forearm cell (j150 % ; P 0.01), disposal into protein synthesis (j100 % ; P 0.01), net intracellular retention (P 0.01), net forearm balance (by $ 6-fold ; P 0.01) and net deamination to α-ketoisocaproate (4-methyl-2-oxopentanoate) (j9 % ; P 0.05). Leucine release from forearm proteolysis and outflow from the forearm cell were unchanged. In contrast, hyperinsulinaemia alone decreased plasma leucine concentrations (k35 % ; P 0.001) and leucine inflow (k20 % ; P 0.05) and outflow (k30 % ; P 0.01) into and out of forearm cell(s), it increased net intracellular leucine retention (P 0.03), and it did not change leucine release from forearm proteolysis (k20 % ; P l 0.138), net leucine deamination to α-ketoisocaproate, leucine disposal into protein synthesis or net forearm protein balance. By considering all data together, leucine disposal into protein synthesis was directly correlated with leucine inflow into the cell (r l 0.71 ; P 0.0001). These data indicate that the infusion of BCAA-enriched, AAAdeficient amino acids along with insulin is capable of stimulating forearm (i.e. muscle) protein anabolism in normal volunteers by enhancing intracellular leucine transport and protein synthesis. These effects are probably due to hyperaminoacidaemia and/or its interaction with hyperinsulinaemia, since they were not observed under conditions of hyperinsulinaemia alone.
INTRODUCTION
Muscle wasting complicates many catabolic diseases [1, 2] , and any treatment aimed at increasing muscle mass may be desirable under these conditions. Both amino acids demonstrated to decrease muscle proteolysis [5] , to increase muscle protein synthesis in some [7, 11] , although not all [4] [5] [6] 10, 13] , studies, and to improve overall net muscle amino acid balance [4] . In general, the anabolic effects of hyperaminoacidaemia on muscle proteins are enhanced by concurrent hyperinsulinaemia, and vice versa [3] [4] [5] [6] [7] [8] [9] [10] . Therefore both a hormonal and a substratemediated stimulation are important, as occurs physiologically after ingestion of mixed meals.
Most studies on the effects of hyperaminoacidaemia (with or without hyperinsulinaemia) on muscle protein turnover in humans have been carried out using balanced amino acid mixtures [7] [8] [9] 12, 15] . However, for some pathological conditions in humans, particularly chronic liver disease [16] , mixtures enriched in branched-chain amino acids (BCAA) and deficient in aromatic amino acids (AAA) are preferentially employed, with the purpose of both stimulating anabolism and correcting the altered amino acid profile which is characteristic of this disease. Furthermore, the BCAA, particularly leucine, have been advocated as potentially direct anabolic substrates [17] [18] [19] . Nevertheless, whether and to what extent BCAA-enriched amino acid mixtures, in combination with insulin, are capable of enhancing muscle protein synthesis in humans has not been specifically studied.
To this aim, we have employed forearm arterio-venous catheterization and the leucine tracer technique in postabsorptive humans, before and after the systemic infusion of BCAA-enriched, AAA-deficient amino acids together with insulin and the euglycaemic clamp. The effects of isolated hyperinsulinaemia were also evaluated. The use of a compartmental forearm leucine model [20] allowed us to investigate leucine kinetics in detail, including transmembrane exchange and transamination.
METHODS

Isotopes
L-[1-"%C]Leucine
(55 mCi\mmol) and Na"%CO $ (50 mCi\mmol) were purchased from Amersham. L-["&N]Leucine ( 99 % mol % enrichment) was purchased from Tracer Technologies (Somerville, MA, U.S.A.). All isotopes were proven to be sterile and pyrogen-free before use.
Experimental design
A total of 13 healthy male volunteers (age 22-40 years ; body mass index 22-25 kg\m#) were admitted to our metabolic unit after an overnight fast. The protocol was explained in detail to each subject, who signed a written consent form. The study was approved by the Dean of the Medical Faculty and by the Director of the Department, and was carried out in accordance with the recommendations of the Declaration of Helsinki and of the local Radiation Safety Officer. The whole-body radiation dose was estimated to be $ 100 mRad [21] .
Polyethylene catheters were placed percutaneously into a brachial artery and, in a retrograde fashion, into an ipsilateral deep forearm vein of the elbow, until the tip of the catheter was no longer palpable under the skin. This vein drains blood predominantly from muscle tissue [4, 20] . An additional catheter was placed into an antecubital vein of the opposite arm for isotope, insulin, amino acid and glucose infusions. The data for forearm leucine uptake and release, using a ' conventional ' arterio-venous model, from five out of the seven subjects infused with insulin (see below) have been reported previously [4] .
At k180 min, primed continuous infusions of ["%C]leucine and of ["&N]leucine were started by means of a calibrated pump (Harvard Apparatus, South Natick, MA, U.S.A.). The constant rate of ["%C]leucine infusion was $ 4200 or 5600 d.p.m.:min −" :kg −" , and that of ["&N]leucine was $ 0.14 or 0.15 µmol:min −" :kg −" , for groups 1 and 2 respectively (see below). The corresponding isotope priming doses were $ 30 times or $ 60 times respectively the corresponding continuous infusion rate per min. Venous plasma samples were taken every 30 min for 150 min (to k30 min). Thereafter, between k30 and 0 min, i.e. at the achievement of a steady state of substrate and isotope concentrations (Figure 1 ), four ' basal ' samples of arterial and deep-venous blood, as well as of expired "%CO # , were collected. Steady state was defined as the absence of a slope significantly different from 0, in addition to the absence of changes of more than 5 %, between the k30 and the 0 min samples, and this was effectively attained in this period despite the different priming doses (Figure 1 ). During sample collection, blood flow to the hand was prevented using a paediatric sphyngomanometer placed around the wrist and gently inflated above systolic pressure. The arterial sample was collected starting a few seconds after completion of venous sampling, in order to avoid acute forearm hypoperfusion.
An euglycaemic, hyperinsulinaemic clamp was performed, either with (n l 6 ; group 1) or without (n l 7; group 2) simultaneous amino acid infusion, for 180 min. Insulin was diluted in 0.9 % (w\v) NaCl, with the addition of 2 ml of the patients' own blood to prevent adsorption to the plastic syringe, and infused into both groups at a rate of 0.05 unit:min −" :m −# . The composition of the L-amino acid solution infused into subjects in group 2 (L-Amino Acidi Selettivi ; Boehringer Mannheim Italia SPA, Milan, Italy) was as follows (mmol\l) : alanine 84.3, arginine 34.5, phenylalanine 6.1, glycine 120, isoleucine 68.7, histidine 15.5, leucine 83.4, lysine 41.6, methionine 6.7, proline 69.6, serine 47.6, threonine 37.8, tryptophan 3.7 and valine 71.8. The rate of exogenous leucine administration with the amino acid solution was 1.95p0.13 µmol:min −" :kg −" , and the rate of adminis-Branched-chain amino acids and muscle turnover 
Analytical measurements
Blood was collected into EDTA tubes and rapidly centrifuged (2500 rev.\min for 15 min) at 4 mC. The plasma was stored at k20 mC. Concentrations and specific radioactivities of plasma leucine and α-ketoisocaproate (KIC ; 4-methyl-2-oxopentanoate) were determined by HPLC, as described elsewhere [20] . Most HPLC samples were run in duplicate. ["&N]Leucine enrichment was determined by gas chromatographymass spectrometry, as t-butyldimethylsilyl derivatives, using electron-impact ionization as described elsewhere [20] , and was expressed as mol % enrichment, i.e. as the tracer\tracerjtracee ratio (see Appendix). Isotope concentrations were obtained by multiplying specific radioactivity or mol % enrichment by the concentration of unlabelled substrate. Plasma flow was determined with a dye-dilution method as described previously [4, 20, 22] . Forearm mass ($ forearm volume) was measured by anthropometry as a truncated cone, with exclusion of the hand. Arterial and deep-venous concentrations of blood
["%C]bicarbonate [20] and "%CO # production in the expired air [23] were determined as described previously. No fixation factor for blood arterio-venous ["%C]bicarbonate was adopted [20] , whereas a wholebody bicarbonate fixation factor of 20 % was employed.
Although such a factor should theoretically be determined in each individual for each different experimental design, the lack of modification of this factor during insulin infusion [24] , as well as the large increase in expired "%CO # observed during hyperaminoacidaemia (see the Results section), probably makes such an experimental validation unnecessary. Insulin and glucagon were determined by radioimmunoassay as described previously [23] . Selected plasma amino acid concentrations were determined by HPLC [23] .
Calculations and data presentation
The forearm kinetics data were calculated by averaging the four steady-state values for both the basal and the infusion periods ( Figure 1 ; Table 1 ), and were expressed as nmol:min −" :100 ml −" forearm. Forearm leucine and KIC kinetics were calculated using a six-compartment model [20] . Model assumptions and equations are given in the Appendix. Extrapolations from the forearm to total-body muscle were performed using standard assumptions [4, 20] . Whole-body leucine kinetics were calculated using the reciprocal pool model [25] and standard equations [26] .
Statistical analysis
All data are expressed as meanspS.E.M. Statistical analysis (comparisons between two sets of data from the same subjects) was performed using the two-tailed paired Student's t test when data distribution was normal, or the Wilcoxon Test when distribution was not normal. Twoway analysis of variance (ANOVA) for repeated measurements was also employed in simultaneous comparisons between groups. A P value of 0.05 was considered to be statistically significant.
RESULTS
Forearm protein synthesis, degradation and net balance
In the fasting state, the forearm was in a negative leucine (i.e. protein) balance in both groups (Table 2) , as leucine release from protein degradation (F5 ; see Appendix and Table 2 for defintions of rates F1-F12) exceeded by $ 15k30 % (P 0.03 and P 0.01 in groups 1 and 2 respectively) disposal into protein synthesis (F6).
Following the infusion of BCAA-enriched amino acids Shown are changes compared with baseline values (expressed as nmol:min − 1 :100 ml − 1 forearm) of leucine disposal into forearm protein synthesis (hatched bars) and of net leucine balance (solid bars), following infusion of either BCAA-enriched, AAA-deficient amino acids plus insulin (group 1 ; left panels) or insulin alone (group 2 ; right panels). Significance of difference compared with basal : *P 0.05.
plus insulin (group 1), leucine disposal into protein (F6) increased by $ 100 % (P 0.01) ( Table 2 ; Figure 2 ), while release from protein degradation (F5) did not change (k4 % ; not significant) ( Table 2 ). Net leucine balance became positive, from k13p6 to j64p12 nmol:min −" :100 ml −" forearm (P 0.02), an increase of $ 77 nmol:min −" :100 ml −" forearm ( Figure  2 ).
Figure 3 Leucine inflow, release and retention
Shown are changes compared with baseline values (expressed as nmol:min − 1 :100 ml − 1 forearm) of leucine inflow from forearm arterial plasma into the cell (F2 ; hatched bars), of leucine release from the cell into venous plasma (F3 ; solid bars), and of net leucine retention (F2kF3 ; double-hatched bars), following either infusion of either BCAA-enriched, AAA-deficient amino acids plus insulin (group 1 ; left panels) or insulin alone (group 2 ; right panels). Significance of differences compared with basal : *P 0.05.
Following hyperinsulinaemia alone (group 2), both leucine release from protein degradation (F5) and disposal into protein (F6) (Figure 2 ) tended to decrease, although to a statistically insignificant extent [k20 % (P l 0.138) and k4% (P 0.5) respectively] ( Table 2) . Net leucine balance improved slightly (P l 0.07), by $ 22 nmol:min −" :100 ml −" forearm ( Figure 2 ), but remained negative (Table 2 ) (P 0.01 by ANOVA compared with group 1).
Forearm leucine transmembrane exchange, transamination and oxidation
In the fasting state, leucine outflow from the forearm cell into the vein (F3) (98.0p14.7 nmol:min −" :100 ml −" ) was greater (P 0.05) than the inflow from the artery (F2) (92.4p13.2 nmol:min −" :100 ml −" ) when all baseline data were considered together. In group 2, however, there was no significant difference between F2 and F3 ( Table 2) , because of two cross-over values. Leucine deamination to KIC (F7) was greater (P 0.01) than KIC reamination into leucine (F8) in both groups, indicating net conversion of leucine into KIC (Table 2) .
Following the infusion of BCAA-enriched amino acids plus insulin (group 1), leucine inflow from artery into cell (F2) increased (P 0.01) by $ 2-fold (Table 2 ; Figure 3) , whereas outflow from cell into vein (F3) did not change (Table 2 ; Figure 3) . The difference between F2 and F3, which indicates net leucine retention by cells, increased markedly (P 0.001) from the post-absorptive value of 0p3 to 87p12 nmol:min −" :100 ml −" forearm. By combining the baseline and the post-infusion data, F2 (leucine inflow) was positively correlated with F6 (leucine disposal into protein synthesis ; r l 0.77, P 0.01) Upper panel : correlation between the rate of leucine inflow into the cell (F2) and leucine disposal into forearm protein synthesis (F6) in all subjects. Lower panel : correlation between the rate of arterial leucine delivery (F1) and leucine inflow (F2) in all subjects. Units are nmol:min − 1 :100 ml − 1 forearm in all cases.
( Figure 4, upper panel) . A significant correlation was also found between F1 (arterial leucine delivery) and F2 (r l 0.61, P 0.02) (Figure 4, lower panel) . Leucine deamination to KIC (F7) increased by $ 50 %, although this change did not reach statistical significance (Table 2) , KIC reamination to leucine (F8) did not change (Table  2) , and net leucine transamination increased by j9p4 nmol:min −" :100 ml −" (P 0.05). The rate of leucine deamination to KIC remained greater (P 0.05) than that of KIC reamination to leucine. Leucine oxidation (F9) decreased in three subjects and increased in the other three, resulting in no significant change overall (Table 2) .
Following infusion of insulin alone (group 2), leucine inflow into (F2) and outflow from (F3) the cell were reduced, by $ 20 % (P 0.05) and $ 30 % (P 0.01) respectively (Table 2 ; Figure 3) . The difference between inflow (F2) and outflow (F3), indicating net leucine Significance of differences compared with baseline values : *P 0.05 ; **P 0.02 ; ***P 0.01. Abbreviations : Leu R a pl , leucine R a into plasma, estimated using the ' primary-pool ' model ; Leu Ra ic , intracellular leucine R a, estimated using the ' reciprocal-pool ' model ; [N]Leu R a, leucine R a estimated using the [ 15 N]leucine isotope ; Leu Ox, leucine oxidation, calculated using the plasma KIC specific radioactivity ; Leu PS, utilization of non-oxidized leucine (for protein synthesis, PS), calculated by subtracting Leu Ox from Leu Ra ic . Significance of differences compared with baseline values : *P 0.05 and **P 0.01. (Figure 3) . The rates of leucine deamination into KIC (F7) and of KIC reamination into leucine (F8) were not significantly modified by insulin, with F7 remaining significantly greater (P 0.05) than F8 (Table 2) ; net transamination did not change either (Table 2) . Leucine oxidation (F9) was also unchanged (Table 2 ).
Hormone and amino acid concentrations, forearm blood flow and substrate exchange
Following infusion of BCAA-enriched amino acids plus insulin (group 1), the plasma insulin concentration was increased by $ 10-fold from the baseline value to $ 100 µ-units\ml, while the glucagon concentration did not change ( Table 3 ). The rate of exogenous glucose infusion required to maintain euglycaemia was 7.3p1.0 mg:min −" :kg −" . Arterial concentrations of leucine and other amino acids increased to a variable extent (by $ 25-240 % ; P 0.05 or less compared with baseline), but that of KIC did not change (Tables 1 and 3 ; Figure 1 ). The arterial leucine concentration was $ 12 % greater than the venous value, indicating net leucine uptake (Table 1 ). In contrast, the venous KIC concentration was significantly greater than that in the artery, indicating net release (Table 1) . Forearm plasma flow was increased by $ 30 % (P 0.05) ( Table 1) .
Following infusion of insulin alone (group 2), the insulin concentration was increased by $ 10-fold (P 0.01), as in group 1, while the glucagon concentration decreased slightly (by $ 30 %) but significantly (Table 3) . Euglycaemia was maintained by a variable exogenous glucose infusion, which averaged 9.0p3.3 mg:min −" :kg −" at steady state. This rate of glucose infusion was $ 20 % greater (P 0.05) than that observed with hyperaminoacidaemia plus hyperinsulinaemia, as shown previously [23] .
Systemic hyperinsulinaemia reduced (P 0.01) arterial plasma concentrations of KIC, leucine, phenylalanine and other amino acids (Tables 1 and 3) . The arteriovenous concentration difference for leucine and KIC shifted from a fasting negative value to near zero ( Table  1) . Forearm plasma flow was slightly but insignificantly increased by insulin (Table 1) .
Whole-body leucine kinetics
Following infusion of BCAA-enriched amino acids plus insulin (group 1), total leucine rate of appearance (Ra) increased by $ 70 % (P 0.01), leucine-nitrogen Ra increased by $ 100 % (P 0.01) (Table 4) , leucine oxidation increased by $ 4-fold (P 0.001), and nonoxidized leucine disposal increased by $ 25 % (P 0.05) ( Table 4) . Following hyperinsulinaemia alone, leucine Ra decreased by $ 18k22 % (P 0.01) (Table 4) , while leucine-nitrogen Ra decreased by $ 30 % (P 0.01). Leucine oxidation did not change. Therefore nonoxidized leucine disposal decreased (P 0.01) by $ 20 % (Table 4 ).
DISCUSSION
Our study shows that infusion of BCAA-enriched, AAA-deficient amino acids plus insulin promoted protein accretion across the human forearm. This effect was achieved through a 2-fold stimulation of muscle protein synthesis, in the absence of changes in protein degradation. The increase in muscle protein synthesis was directly correlated with that of leucine inflow from plasma into forearm cell(s). Only minor changes were observed in other leucine metabolic pathways, such as transamination and oxidation. The protein-anabolic effect was probably due to hyperaminoacidaemia, since systemic hyperinsulinaemia in the absence of amino acids (group 2) did not elicit any stimulation of forearm protein synthesis or of leucine inflow into cells.
In a previous study [11] , local hyperinsulinaemia stimulated both leucine transport and protein synthesis in the leg. The discrepancies with our findings might be due to the marked decrease in leucine levels achieved in our study, at variance with the minor change described in [11] . Also, differences in the route of insulin administration (local compared with systemic), as well as in the model used, may account for these variances. It should be noted, however, that the role of insulin in stimulating muscle protein synthesis in humans is highly controversial [4] [5] [6] [7] 10, 11, 13, 22] , whereas stimulation of both protein synthesis [6] [7] [8] [9] 12, 14, 15] and transport [12] has been observed with hyperaminoacidaemia, in agreement with the present findings ( Table 2) . Thus muscle protein anabolism is driven mainly by the increase in amino acid concentration, as well as their delivery into muscle.
Following an infusion of BCAA, Louard et al. [27] found a dramatic decrease in the concentrations of many amino acids, including phenylalanine (with the exception of the BCAA that were infused), decreases in both forearm protein synthesis and degradation (based on phenylalanine data), and increases in forearm leucine balance and disposal. Since leucine oxidation was not measured, forearm protein synthesis and net balance could not be determined. Also, the phenylalanine data were hampered by the dramatic decrease in the phenylalanine concentration following the BCAA infusion. For these reasons, an overall interpretation of these findings is difficult.
Although we chose intentionally to infuse an unbalanced amino acid solution which is used frequently for liver disease patients [28] and is deficient in some amino acids, these deficiencies might theoretically have limited our conclusions. Indeed, glutamine, tyrosine and tryptophan were absent, while phenylalanine was infused at a relatively low level. Glutamine and tyrosine are usually either absent or highy reduced even in ' balanced ' amino acid solutions [6] [7] [8] [9] [10] [13] [14] [15] 23, 29, 30] , because of either poor stability or poor solubility [31, 32] . Although the phenylalanine content in the infused solution was low, the plasma concentration of this amino acid was almost unchanged (Table 3) ; therefore it was unlikely to be rate-limiting in protein synthesis. Despite this, we found a net increase in forearm leucine balance (j77 nmol:min −" :100 ml −" forearm), nearly identical to that observed by Bennet et al. [7, 9] using a more balanced solution (j73 nmol:min −" :100 ml −" leg). In our study, we infused 1 mmol\min total amino acids, 12 % of which was represented by leucine, which was thus infused at a rate of $ 0.12 mmol\min ; under these conditions, plasma leucine increased by $ 70 %. In the studies of Bennet et al. [7, 9] , 1.9 mmol\min total amino acids were infused, 7 % of which was leucine, which was thus infused at a rate of $ 0.13 mmol\min, resulting in an increase in plasma leucine of $ 120 %. Thus, despite some differences in experimental design and in the mechanism(s) involved, it can be concluded that, although partially unbalanced, the BCAA-enriched, AAA-deficient amino acid solution induced an increase in net protein accretion (as judged from leucine data) similar to that observed with more complete amino acid mixtures, which is probably dependent on the rate of infusion of exogenous leucine.
Leucine deamination and reamination were slightly increased under conditions of hyperaminoacidaemia plus hyperinsulinaemia, resulting in a significant increase in net leucine deamination, whereas they tended to be decreased after infusion of insulin alone (Table 2 ; Figure  3 ). These data are consistent with in vitro findings [33] . Leucine oxidation was not changed by either treatment (Table 2) . Thus the excess of leucine converted into KIC in group 1 subjects was released by the forearm as KIC rather than being oxidized (Table 1) . In vitro studies have shown that skeletal muscle has a high BCAA transaminase activity, but a low oxidative capacity [33] [34] [35] . The relative rates of these enzymic activities are reversed in the liver [33] [34] [35] . Our data are compatible with these findings, since the rate of forearm leucine oxidation was between one-half and one-quarter that of leucine deamination (Table 2) , and was not stimulated following hyperaminoacidaemia. Therefore the excess of leucine oxidation following hyperaminoacidaemia is likely to have occurred at extramuscular sites.
We failed to observe a suppression of forearm proteolysis by combined hyperaminoacidaemia and hyperinsulinaemia (Table 2 ), in agreement with other reports [6, 7, 12] . A possible explanation is that the forearm amino acid supply had to be maintained high through endogenous proteolysis, at a time when protein synthesis was stimulated by an amino acid infusion lacking some amino acids (such as tyrosine, glutamine and tryptophan). In the insulin-infusion study, we also failed to find a significant suppression of forearm protein degradation or a significant improvement of net balance (Table 2 ). These findings are in agreement with some [4, 10] , but not all [5, 13] , previous reports. It is possible that the systemic changes in leucine concentration achieved in the ' negative ' studies ( [4, 10] ; the present study) blunted possible effects of insulin on the forearm, in contrast with the unchanged amino acid concentrations of the ' positive ' studies [5, 13] . In addition, the number of subjects used in the present study might be insufficient to detect significant insulin-induced changes (15-16 subjects rather than the seven studied here would be required for a test-power of 80 %).
In a subset of subjects (n l 4) of group 1 only, we performed simultaneous and complete measurements in both plasma and whole blood (results not shown). The leucine kinetic parameters (including transport, transamination, protein synthesis and net balance) were 2-fold greater when measured in whole blood than in plasma (results not shown), thus confirming our previous report [3] . However, the direction of changes following the combined infusion were similar to those detected from plasma measurements. Thus, although probably underestimated, the changes observed in the present study following the infusion of amino acids plus insulin are likely to be qualitatively correct.
In conclusion, infusion of a BCAA-enriched, AAAdeficient amino acid solution plus insulin is capable of stimulating forearm protein synthesis, leucine transport and net transamination in healthy humans. The relative stimulation of muscle net protein accretion appears to be no less than that reported previously with more balanced amino acid mixtures. Systemic hyperinsulinaemia alone modestly (although insignificantly) depressed forearm proteolysis, leucine transmembrane exchange and deamination, but it did not stimulate forearm protein synthesis. Thus these findings also confirm that hyperaminoacidaemia is essential for the enhancement of intracellular leucine transport, protein synthesis and net protein accretion in human skeletal muscle.
APPENDIX Six-compartment model
A brief description of the compartment model employed is given below. A more detailed discussion can be found in the original paper [1] .
To describe leucine and KIC kinetics across the forearm, the following models have been developed : (1) The tracee leucine model is composed of six compartments, three of leucine and three of KIC ( Figure A1 ). The units are nmol:min −" :100 ml −" forearm. For each substrate, one compartment is in the artery, one is intracellular and one is in the vein. The notations F1 and F4 indicate leucine tracee flux in the artery and in the vein respectively. F2, F3 and F12 indicate leucine movements from artery to cell, from cell to vein and from artery directly to vein respectively. F5 indicates release of leucine from protein into the cell, i.e. it is an estimate of intracellular proteolysis. No tracer recycling from pro-Branched-chain amino acids and muscle turnover At steady state, the sum of entries into each compartment (or sum of compartments considered together) must be equal to the sum of exits from each compartment (or sum of compartments respectively). This is true for both the unlabelled and the labelled moieties (see below), both under fasting conditions and after the equilibrium has been achieved following amino acid and\or insulin infusion, i.e. at steady state (see Figure 1 of the main paper). Therefore mass-balance equations can be used.
The principal assumptions of the model are as follows. Clearly this is an approximation, because the SA of venous ["%C]KIC may be greater than either the SA of intracellular leucyl-tRNA (i.e. the immediate precursor of protein synthesis) or the SA of tissue-free leucine [2] [3] [4] [5] [6] . Such a difference may vary from a minimum of 5 % [2] to a maximum of 23-30 % [6] . Furthermore, we assume a single, well mixed intracellular leucine pool, whereas functional heterogeneity of these pools is more likely [6] . Nevertheless, when muscle biopsies cannot be taken, as in the present study, the deep-venous KIC is the closest precursor of the intracellular leucine pool(s) that can be measured from plasma samples.
(b) The fraction of the ["&N]leucine tracer irreversibly disposed from the plasma into the cell, calculated from the arterial-venous difference of ["&N]leucine isotope concentrations, is assumed to represent the ' net metabolic leucine utilization '. This value is used to calculate inwards and outwards movements of leucine across the cell membrane. These movements may underestimate leucine transport across the cell membrane, to the extent that the ["&N]leucine tracer either is recycled back to the venous compartment without being metabolized, or (more unlikely) is derived from KIC reamination. Conversely, the fraction of ["&N]leucine tracer not taken up by the forearm is assumed to bypass intracellular metabolism and to be released directly into the vein. This value will be applied to calculate the fraction of unlabelled leucine that escapes intracellular metabolism.
(c) No interstitial compartment is considered. The ["%C]leucine, ["%C]KIC and ["&N]leucine isotopes are assumed to enter their corresponding intracellular compartments at the arterial concentrations ; similarly, they are assumed to be released from their intracellular compartments at the measured deep-venous concentrations.
(d) No release of tracer(s) recycled from protein breakdown into the intracellular leucine compartment is assumed to take place within the duration of the study. (e) There is no independent production of KIC inside the cell, except that derived from leucine and from blood. (f) Finally, we assume that the metabolic behaviour of the "%C-labelled tracer(s) is the same as that of unlabelled material.
In the following equations, Leu (nmol\ml) Given these assumptions and definitions, all the F and f transport rates can be solved using the following equations.
(a)"%C-tracer model. Leucine net balance is then calculated as :
(24) Leu net balance l F5kF6
